Overview

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Study to establish the lung function effects of added formoterol (12μg QD and BID) during 2-week periods to pharmacodynamic steady state of tiotropium(18μg QD)

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Formoterol Fumarate
Tiotropium Bromide